MIDATECH PHARMA PLC SPON ADS EACH REP 5 ORD BDRX 深 沪
已收盘 04-02 16:00:00 美东时间
0.8733
+0.259
+42.23%
华盛通- 最 高1.35
- 今 开0.9235
- 成交量 1.21亿股
- 最 低 0.8008
- 昨 收 0.614
- 总市值 283.09万
- 52周最高 19.30
- 市盈率 静 --
- 换手率 3739.28%
- 52周最低 0.6005
- 委 比 -69.95%
- 总股本 324.16万
- 历史最高 159417654.2112
- 量 比 1574.62
- 振 幅 89.45%
- 历史最低 0.6005
- 每 手 1
- 风险率 4.34%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Why Is Biodexa Pharmaceuticals (BDRX) Stock Skyrocketing Today?
Biodexa Pharmaceuticals shares are trading sharply higher Thursday afternoon after the company said it partnered with Syngene International.
今天 01:15
Biodexa Pharma Partners With Syngene International To Manufacture Both MTX240 Active Pharmaceutical Ingredient And Dosage Form
Biodexa Announces Partnership with SyngeneTo Manufacture MTX240 GMP Clinical Trial SuppliesBiodexa Pharmaceuticals PLC (NASDAQ:BDRX) ("Biodexa" or "Company"), a clinical stage biopharmaceutical company developing a
04-02 20:37
Biodexa Pharmaceuticals To Implement 1-For-5 Reverse ADR Split, Changing ADR Ratio From 1:100,000 To 1:500,000 Ordinary Shares Effective April 6, 2026
Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of rare diseases with unmet medical needs, today announces a ratio
03-19 05:02
Biodexa Pharmaceuticals Adds New Phase 1 Ready Candidate To Its Portfolio To Treat Gastrointestinal Stromal Tumors
Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), a clinical-stage biopharmaceutical company developing a pipeline of innovative products for the treatment of rare diseases with an increasing focus on products to treat or
02-19 20:33
Biodexa Pharmaceuticals Prices $10M Public Offering, Selling 157,000 ADS Units At $3.28 And 2.89M Pre-Funded Units
Biodexa Announces Pricing of $10 Million Public OfferingBiodexa Pharmaceuticals PLC, (NASDAQ:BDRX) ("Biodexa" or the "Company"), a clinical stage biopharmaceutical company developing a pipeline of innovative products for
2025-12-18 21:40
Biodexa Prices $10M Public Offering
Biodexa Pharmaceuticals PLC, (NASDAQ:BDRX) ("Biodexa" or the "Company"), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs,
2025-12-18 21:38
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Biodexa Pharmaceuticals (NASDAQ:BDRX) shares moved upwards by 38.7% to...
2025-12-16 20:05
Biodexa Pharmaceuticals Advances Serenta Trial and Secures Financial Backing
An announcement from Biodexa Pharmaceuticals ( ($BDRX) ) is now available. Biod...
2025-09-12 21:33
Biodexa Pharmaceuticals GAAP EPS of -£0.0002
Biodexa Pharmaceuticals press release (NASDAQ:BDRX): 1H GAAP EPS of -£0.0002. Net cash used in operating activities (after changes in working capital) in 1H25 was £3.30 million (1H24: £4.81 million). ...
2025-09-12 20:43
Biodexa Pharmaceuticals Begins Phase 3 Trial for FAP Treatment
Biodexa Pharmaceuticals ( ($BDRX) ) just unveiled an announcement. On August 18...
2025-08-18 20:57
